Chemotherapie: Offener Zugang
Offener Zugang

Abstrakt

The First Case of Decitabine Successfully in Treatment of Atypical Chronic Myeloid Leukemia with CEBPA Double Mutation

Liping Mao, Liangshu You, Min Yang, Ying Li, XingNong Ye and HongYan Tong

Background: Atypical chronic myeloid leukemia (aCML) treated with decitabine is never reported. Methods: We admitted a 69-year-old man with splenomegaly, hyperleucocytosis, thrombocytopenia and anemia, then morphology, immunology, cytogenetics and molecular biology analysis of bone marrow were performed and the diagnosis of aCML was made. The patient was initially treated with decitabine chemotherapy (20 mg/m2×5 days). The patient achieved complete hematology and morphologic remission after three cycle’s treatment. Results: The data demonstrated that the diagnosis was aCML, which may be misdiagnosed easily. The patient responded very well to decitabine. Conclusion: This case provides evidence that decitabine is effective for therapy in aCML, and demonstrated a new safety and efficacy strategy in the management of other myeloproliferative diseases.